English, Article edition: The Cost of Lung Cancer Management in France from the Payor's Perspective Alain Vergnenegre; Laurent Molinier; Christophe Combescure; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/92682
Physical Description
  • article
Language
  • English

Edition details

Title
  • The Cost of Lung Cancer Management in France from the Payor's Perspective
Author
  • Alain Vergnenegre
  • Laurent Molinier
  • Christophe Combescure
  • Jean-Pierre Daures
  • Bruno Housset
  • Christos Chouaid
Physical Description
  • article
Notes
  • Background: We assessed the average management cost per case of lung cancer in France according to the histological type and stage at diagnosis, together with the cost of each component of different treatment strategies. Methods: The sample was drawn from public and private hospitals that were treating large numbers of patients. The study covered the period from 1 July 1998 to 30 June 1999 and was based on medical chart review. A Markov model with six decision trees (two for small cell lung cancer [SCLC] and four for non-small cell lung cancer [NSCLC]) was used for the cost analysis. Treatment was broken down into first-line and second-line strategies, surveillance, and terminal care (TC). Results: The average management costs were _22_006 (_10_631-36_296) for 1 year and _25_643 (_10_631-41_191) for 2 years. The 2-year average costs were _22_420 for disseminated SCLC and _27_098 for localized SCLC. The costs of NSCLC ranged from _19_543 for nonsurgical stages to _30_024 for surgical stages and _24_383 for stage IV. The weight of the different components of each strategy differed markedly according to the diagnostic subgroup: the cost of diagnosis ranged from 7.4% to 14% of total management costs, and that of TC from 11.5% to 31.1%. The principal cost component was first-line chemotherapy (32-58.5%). Sensitivity analyses showed that, whatever the type of lung cancer, the percentage of actively treated patients was the main cost determinant. TC and chemotherapeutic lines also had important economic implications. Conclusion: The model developed here enables the component costs of different lung cancer management strategies in France to be assessed and the economic consequences of new treatment modalities to be predicted.
  • Cost-analysis, Lung-cancer, Lung-cancer, Markov-model, Non-small-cell-lung-cancer, Small-cell-lung-cancer
  • RePEc:wkh:dmhout:v:14:y:2006:i:1:p:55-67
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment